ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05274633
- Locations
- 🇮🇹
Clinical Trial Site, Salerno, Italy
Study of ALXN2050 in Participants With Hepatic Impairment
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05259085
- Locations
- 🇺🇸
Research Site, Orlando, Florida, United States
A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05254613
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
A Prospective Sub-Study of the Global Hypophosphatasia Registry
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05234567
- Locations
- 🇺🇸
Clinical Trial Site, Madison, Wisconsin, United States
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Phase 2
Terminated
- Conditions
- Generalized Myasthenia GravisMyasthenia Gravis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05218096
- Locations
- 🇨🇳
Research Site, Taoyuan City, Taiwan
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT05202145
- Locations
- 🇺🇸
Clinical Study Site, Tempe, Arizona, United States
A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Aluminum/Magnesium Hydroxide/Simethicone
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT05109390
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Phase 2
Terminated
- Conditions
- Lupus NephritisIgANLNImmunoglobulin A Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05097989
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
A Study of Multiple Doses of ALXN2050 in Healthy Adults
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05047484
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
A Study of Single-dose ALXN2050 in Healthy Adults
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05047458
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
© Copyright 2025. All Rights Reserved by MedPath